Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
STOCKHOLM, SWEDEN - January 16, 2025 - OncoZenge AB (publ) ("OncoZenge" or the "Company"), announces the filing of a patent application under the Patent Cooperation Treaty (PCT) process, a significant milestone in the intellectual property strategy for the company's lead drug candidate, BupiZenge™. This filing follows the patent application submitted with priority with the Swedish Patent and Registration Office (PRV) in February of 2024, in line with international PCT requirements.
The PCT process is a crucial step toward obtaining broad international patent protection, offering the opportunity to secure patents across multiple jurisdictions. For BupiZenge™, this milestone underlines OncoZenge's commitment to delivering its innovative therapeutic solution to a worldwide market.
"Filing the PCT patent application is a strategically important achievement as it strengthens the foundation for our global patent coverage," said Stian Kildal, CEO of OncoZenge. "Such protection is essential for attracting and supporting our licensees and ensuring the successful commercialization of BupiZenge in key markets worldwide."
The new patent, when granted, will provide coverage until 2045 and complements OncoZenge's existing portfolio of granted patents.
BupiZenge™ - Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se
Certified Adviser
OncoZenge's Certified Adviser is Redeye AB.
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About OncoZenge
OncoZenge is dedicated to developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options fall short, often due to insufficient pain relief or significant side effects. BupiZenge™ is a novel oral lozenge formulation of bupivacaine, a local anesthetic with decades of clinical experience. The lead indication for BupiZenge™ is oral pain caused by oral mucositis, an inflammatory condition affecting millions of cancer patients. Oral mucositis leads to severe physical and psychological distress, representing a significant unmet medical need for an effective, opioid-sparing treatment. In Phase 2 trials, BupiZenge™ demonstrated substantially better pain relief compared to the standard of care.
OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.